See the published version of this preprint at Respiratory Research.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
Research
Tatsuya Nagano
Kobe University Graduate School of Medicine
Corresponding Author
ORCiD: https://orcid.org/0000-0003-0790-5139
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: Recent studies have revealed that serpin peptidase inhibitor clade E member 2 (SERPINE2) is associated with tumorigenesis. However, SERPINE2 expression and its role in lung adenocarcinomas are still unknown.
Methods: The expression levels of SERPINE2 in 74 consecutively resected lung adenocarcinomas were analyzed by using immunostaining. Inhibition of SERPINE2 expression by small interfering RNA (siRNA) was detected by quantitative PCR. Cell number assays and cell apoptosis assays were performed to clarify the cell-autonomous function of SERPINE2 in A549 and PC9 lung cancer cells.
Results: The overall survival of patients with high SERPINE2 expression was significantly worse than that of patients with low SERPINE2 expression (P=0.0172). Multivariate analysis revealed that SERPINE2 expression was an independent factor associated with poor prognosis (P=0.03237). The interference of SERPINE2 decreased cell number and increased apoptosis in A549 and PC9 cells
Conclusion: These results suggest that SERPINE2 can be used as a novel prognostic marker of lung adenocarcinoma.
Keywords
serpin peptidase inhibitor clade E member 2, lung cancer, adenocarcinoma
Figure 1
Figure 1
Figure 1
Figure 1
Figure 1
Figure 1
This is a list of supplementary files associated with this preprint. Click to download.
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at Respiratory Research.
Version 2
Posted 17 Dec, 2020
No community comments so far
Editorial decision: Accept
On 05 Dec, 2020
Review #1 received
Received 04 Dec, 2020
Review #2 received
Received 03 Dec, 2020
Reviewer #2 agreed
On 29 Nov, 2020
Reviewers invited
Invitations sent on 29 Nov, 2020
Reviewer #1 agreed
On 29 Nov, 2020
Editor assigned
On 28 Nov, 2020
Submission checks complete
On 28 Nov, 2020
Editor invited
On 28 Nov, 2020
No comments provided
Editorial decision: Major revision
On 09 Nov, 2020
Review #1 received
Received 08 Nov, 2020
Review #2 received
Received 08 Nov, 2020
Reviewer #1 agreed
On 26 Oct, 2020
Reviewer #2 agreed
On 26 Oct, 2020
Reviewers invited
Invitations sent on 31 Aug, 2020
Editor assigned
On 31 Jul, 2020
First submitted
On 30 Jul, 2020
Submission checks complete
On 30 Jul, 2020
Editor invited
On 30 Jul, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Health Economics & Outcomes Research
Learn more about our company.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
See the published version of this preprint at Respiratory Research.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research
Tatsuya Nagano
Kobe University Graduate School of Medicine
Corresponding Author
ORCiD: https://orcid.org/0000-0003-0790-5139
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at Respiratory Research.
Version 2
Posted 17 Dec, 2020
No community comments so far
Editorial decision: Accept
On 05 Dec, 2020
Review #1 received
Received 04 Dec, 2020
Review #2 received
Received 03 Dec, 2020
Reviewer #2 agreed
On 29 Nov, 2020
Reviewers invited
Invitations sent on 29 Nov, 2020
Reviewer #1 agreed
On 29 Nov, 2020
Editor assigned
On 28 Nov, 2020
Submission checks complete
On 28 Nov, 2020
Editor invited
On 28 Nov, 2020
No comments provided
Editorial decision: Major revision
On 09 Nov, 2020
Review #1 received
Received 08 Nov, 2020
Review #2 received
Received 08 Nov, 2020
Reviewer #1 agreed
On 26 Oct, 2020
Reviewer #2 agreed
On 26 Oct, 2020
Reviewers invited
Invitations sent on 31 Aug, 2020
Editor assigned
On 31 Jul, 2020
First submitted
On 30 Jul, 2020
Submission checks complete
On 30 Jul, 2020
Editor invited
On 30 Jul, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Health Economics & Outcomes Research
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published article at Respiratory Research.
Background: Recent studies have revealed that serpin peptidase inhibitor clade E member 2 (SERPINE2) is associated with tumorigenesis. However, SERPINE2 expression and its role in lung adenocarcinomas are still unknown.
Methods: The expression levels of SERPINE2 in 74 consecutively resected lung adenocarcinomas were analyzed by using immunostaining. Inhibition of SERPINE2 expression by small interfering RNA (siRNA) was detected by quantitative PCR. Cell number assays and cell apoptosis assays were performed to clarify the cell-autonomous function of SERPINE2 in A549 and PC9 lung cancer cells.
Results: The overall survival of patients with high SERPINE2 expression was significantly worse than that of patients with low SERPINE2 expression (P=0.0172). Multivariate analysis revealed that SERPINE2 expression was an independent factor associated with poor prognosis (P=0.03237). The interference of SERPINE2 decreased cell number and increased apoptosis in A549 and PC9 cells
Conclusion: These results suggest that SERPINE2 can be used as a novel prognostic marker of lung adenocarcinoma.
Figure 1
Figure 1
Figure 1
Figure 1
Figure 1
Figure 1
This is a list of supplementary files associated with this preprint. Click to download.
Loading...